NasdaqGM:TRVIPharmaceuticals
Assessing Trevi Therapeutics (TRVI) Valuation After New Chronic Cough Data Plans At ATS 2026
Trevi Therapeutics (TRVI) is drawing attention after announcing upcoming oral and poster presentations at the American Thoracic Society 2026 International Conference, which will focus on new clinical data for its investigational chronic cough treatment.
See our latest analysis for Trevi Therapeutics.
The latest share price of US$13.87 sits alongside a 30 day share price return of 16.16% and a 90 day gain of 26.55%. The 1 year total shareholder return of 98.43% and 3 year total shareholder...